Literature DB >> 2320397

Xanthine oxidase during human fetal development.

K Vettenranta1, K O Raivio.   

Abstract

Through oxygen free-radical production, xanthine oxidase (XOD, E.C.1.2.3.2) has been implicated in the pathogenesis of postischemic and hyperoxic tissue injuries among newborn. We measured the activity and evaluated the kinetic characteristics of XOD in human fetal liver, intestine, brain, and myocardium. Both the fetal liver and intestine contain a high XOD activity through gestation. The activity increases in the liver and decreases in the intestine with advancing gestation. The apparent Km for hypoxanthine is 4.8-5.5 microM in the intestine throughout gestation and in the liver at term but higher than 30 microM in the liver during the first half of pregnancy. The activity is undetectable both in the fetal brain and myocardium throughout gestation. Thus, XOD activity is present at least in the liver and intestine to account for the oxidation of hypoxanthine and xanthine. However, direct evidence for adenine nucleotide catabolism, followed by oxidation of the accumulated hypoxanthine during tissue reoxygenation in the human liver or intestine is not available.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2320397     DOI: 10.1203/00006450-199003000-00017

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  5 in total

1.  Neuronal nitric oxide synthase inhibition prevents cerebral palsy following hypoxia-ischemia in fetal rabbits: comparison between JI-8 and 7-nitroindazole.

Authors:  Lei Yu; Matthew Derrick; Haitao Ji; Richard B Silverman; Jennifer Whitsett; Jeannette Vásquez-Vivar; Sidhartha Tan
Journal:  Dev Neurosci       Date:  2011-06-10       Impact factor: 2.984

2.  A tungsten supplemented diet attenuates bacterial translocation in chronic portal hypertensive and cholestatic rats: role of xanthine dehydrogenase and xanthine oxidase.

Authors:  G Schimpl; M A Pabst; G Feierl; A Kuesz; H Ozbey; S Takahashi; M E Höllwarth
Journal:  Gut       Date:  1999-12       Impact factor: 23.059

Review 3.  Predicting Human Fetal Drug Exposure Through Maternal-Fetal PBPK Modeling and In Vitro or Ex Vivo Studies.

Authors:  Ankit Balhara; Aditya R Kumar; Jashvant D Unadkat
Journal:  J Clin Pharmacol       Date:  2022-09       Impact factor: 2.860

4.  Randomised controlled trial of allopurinol prophylaxis in very preterm infants.

Authors:  G A Russell; R W Cooke
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1995-07       Impact factor: 5.747

5.  Oxypurinol pharmacokinetics and pharmacodynamics in healthy volunteers: Influence of BCRP Q141K polymorphism and patient characteristics.

Authors:  Bianca Vora; Deanna J Brackman; Ling Zou; Maria Garcia-Cremades; Marina Sirota; Radojka M Savic; Kathleen M Giacomini
Journal:  Clin Transl Sci       Date:  2021-05-01       Impact factor: 4.689

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.